195 related articles for article (PubMed ID: 18717603)
21. [Cutaneous side effects of EGFR inhibitors--appearance and management].
Wollenberg A; Kroth J; Hauschild A; Dirschka T
Dtsch Med Wochenschr; 2010 Jan; 135(4):149-54. PubMed ID: 20101558
[TBL] [Abstract][Full Text] [Related]
22. EGFR inhibitor-induced folliculitis decalvans: a case series and management guidelines.
Nowaczyk J; Fret K; Kaminska-Winciorek G; Rudnicka L; Czuwara J
Anticancer Drugs; 2023 Sep; 34(8):942-948. PubMed ID: 36708507
[TBL] [Abstract][Full Text] [Related]
23. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
24. Grading of severe follicular rash in patients receiving EGFR inhibitors.
Manganoni AM; Farisoglio C; Ferrari V; Zaniboni A; Beretta G; Meriggi F; Calzavara-Pinton P
Ann Surg Oncol; 2010 Jan; 17(1):349. PubMed ID: 19821000
[No Abstract] [Full Text] [Related]
25. Acneiform eruptions associated with epidermal growth factor receptor-targeted chemotherapy.
DeWitt CA; Siroy AE; Stone SP
J Am Acad Dermatol; 2007 Mar; 56(3):500-5. PubMed ID: 17166623
[TBL] [Abstract][Full Text] [Related]
26. A case report and discussion of cetuximab-induced folliculitis.
Adams DH; Nutt T
Am J Clin Dermatol; 2006; 7(5):333-6. PubMed ID: 17007545
[TBL] [Abstract][Full Text] [Related]
27. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225.
Busam KJ; Capodieci P; Motzer R; Kiehn T; Phelan D; Halpern AC
Br J Dermatol; 2001 Jun; 144(6):1169-76. PubMed ID: 11422037
[TBL] [Abstract][Full Text] [Related]
28. [Epidermal cysts and folliculitis caused by cyclosporin A].
Richter A; Beideck S; Bender W; Frosch PJ
Hautarzt; 1993 Aug; 44(8):521-3. PubMed ID: 8376106
[TBL] [Abstract][Full Text] [Related]
29. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies.
Segaert S; Tabernero J; Chosidow O; Dirschka T; Elsner J; Mancini L; Maughan T; Morere JF; Santoro A; Sobrero A; Van Cutsem E; Layton A
J Dtsch Dermatol Ges; 2005 Aug; 3(8):599-606. PubMed ID: 16033478
[TBL] [Abstract][Full Text] [Related]
30. Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors.
Zhao Q; Shentu J; Xu N; Zhou J; Yang G; Yao Y; Tan F; Liu D; Wang Y; Zhou J
Lung Cancer; 2011 Aug; 73(2):195-202. PubMed ID: 21144613
[TBL] [Abstract][Full Text] [Related]
31. Cutaneous lesions in the rat following administration of an irreversible inhibitor of erbB receptors, including the epidermal growth factor receptor.
Brown AP; Dunstan RW; Courtney CL; Criswell KA; Graziano MJ
Toxicol Pathol; 2008 Apr; 36(3):410-9. PubMed ID: 18467688
[TBL] [Abstract][Full Text] [Related]
32. Clinical research of EGFR inhibitors and related dermatologic toxicities.
Perez-Soler R; Van Cutsem E
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):10-6. PubMed ID: 18154213
[TBL] [Abstract][Full Text] [Related]
33. Clinical management of EGFRI dermatologic toxicities: the European perspective.
Segaert S; Van Cutsem E
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):22-6. PubMed ID: 18159647
[TBL] [Abstract][Full Text] [Related]
34. Acneiform eruption induced by cetuximab.
Cotena C; Gisondi P; Colato C; Girolomoni G
Acta Dermatovenerol Croat; 2007; 15(4):246-8. PubMed ID: 18093454
[TBL] [Abstract][Full Text] [Related]
35. [Relationship between the Incidence of Hypomagnesemia and Acneiform Rash and the Therapeutic Effect of Anti-EGFR Monoclonal Antibody in Patients with Metastatic Colorectal Cancer].
Fujii H; Iihara H; Ishihara M; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
Gan To Kagaku Ryoho; 2016 Feb; 43(2):229-33. PubMed ID: 27067688
[TBL] [Abstract][Full Text] [Related]
36. Cutaneous toxicity from epidermal growth factor receptor inhibitors: would a subcutaneous desensitization be helpful? Case report.
D'Alessio A; Cecchini S; Di Mauro D; Geroli L; Villa S; Quadri A; Resta D; Fortugno C
Tumori; 2016 Nov; 102(Suppl. 2):. PubMed ID: 27791234
[TBL] [Abstract][Full Text] [Related]
37. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum.
Pérez-Soler R; Delord JP; Halpern A; Kelly K; Krueger J; Sureda BM; von Pawel J; Temel J; Siena S; Soulières D; Saltz L; Leyden J
Oncologist; 2005 May; 10(5):345-56. PubMed ID: 15851793
[TBL] [Abstract][Full Text] [Related]
38. Extreme Phenotype of Epidermal Growth Factor Receptor Inhibitor-induced Destructive Folliculitis.
Anzengruber F; Meier B; Maul JT; Kerl K; French LE; Navarini AA
Int J Trichology; 2016; 8(4):176-179. PubMed ID: 28442875
[TBL] [Abstract][Full Text] [Related]
39. Grover's disease induced by cetuximab.
Tscharner GG; Bühler S; Borner M; Hunziker T
Dermatology; 2006; 213(1):37-9. PubMed ID: 16778425
[TBL] [Abstract][Full Text] [Related]
40. Common side effects of anti-EGFR therapy: acneform rash.
Sipples R
Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):28-34. PubMed ID: 16616284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
